Tiffany Hamilton

PR strategist, dedicated mom, and all-around fun gal

[Ocugen @Ocugen]

Big news! We’ve dosed the first patient in our Phase 2/3 GARDian3 trial for #Stargardtdisease (OCU410ST). With no approved treatment today, this huge milestone brings us one step closer to helping patients with this blindness disease.

Details: https://t.co/R7hId9bAvo

[Tiffany Hamilton @tiffjeanne]

The best show ever!!!! What a combo.

[The Sting @TheStingisBack]

Moonlighting premiered 40 years ago today.
I was obsessed with this show starring Bruce Willis and Cybil Shepherd, it was sharp, witty, playful and had great music. Here's one of the best openings ever, featuring The Temptations, also Al Jarreau's theme song. Do bears bear...

[Tiffany Hamilton @tiffjeanne]

Encouraging patient testimonials from our OCU410ST Phase 1/2 GARDian clinical trial!

[Ocugen @Ocugen]

Ocugen Chief Medical Officer, Dr. Huma Qamar, shares more about the patient experience after treatment with OCU410ST in the Phase 1/2 GARDian clinical trial for Stargardt disease. #GeneTherapy #Stargardt #IRD #ClinicalTrials

[Tiffany Hamilton @tiffjeanne]

The clinical hold lift on OCU200 marks a significant milestone for Ocugen. We look forward to advancing this biological candidate for DME. #Ocugen

[Ocugen @Ocugen]

Today, Ocugen announced that the FDA has lifted the clinical hold on the investigational new drug application for the Phase 1 clinical trial evaluating OCU200 for treating diabetic macular edema (DME). Read the full press release here: https://t.co/YORev4hFf5

[Tiffany Hamilton @tiffjeanne]

I look forward to joining Arun in NYC next week to meet with the investment community and share more about our cutting edge modifier gene therapy platform. #CourageousInnovation

[Ocugen @Ocugen]

Dr. Arun Upadhyay, Ocugen’s CSO, will participate in a fireside chat at Chardan’s 8th Annual Genetic Medicines Conference in New York, NY. You can participate virtually via webcast: https://t.co/6WGfyZmFE6 the full press release here: https://t.co/T7xSCmJK71

[Tiffany Hamilton @tiffjeanne]

Proud Auntie. #laxaunt

[Midwest Top Gun @MidwestTopGun]

Jack,

No matter where you go in this world 🌎
You will always be a 2x ALL AMERICAN 🇺🇸.

Congratulations on fantastic HS career & Good Luck at the next level . @af_lax @_LancerLacrosse @JackHam050505

[Tiffany Hamilton @tiffjeanne]

This is sure to be a program you won’t want to miss! Space is still available. #ir #pr

[Ocugen @Ocugen]

Join us next week at the Nasdaq Market Site to hear more about Ocugen's modifier gene therapy pipeline, near-term next steps, and physician/patient experiences. To RSVP email [email protected]. #genetherapy #clinicaltrials #ird

[Ocugen @Ocugen]

Today we announced that the FDA has granted RMAT designation to Ocugen’s investigational product OCU400 for the treatment of retinitis pigmentosa (RP) associated with RHO mutations. RMAT designation is a significant accomplishment for the program. https://t.co/9KFqQqbSBU

[Tiffany Hamilton @tiffjeanne]

Another very important milestone for our ophthalmology pipeline! So exciting to be a part of these scientific breakthroughs that have the potential to mean so much for people living with macular degeration. #ocugen #genetherapy #courageousinnovation

[Ocugen @Ocugen]

Today, Ocugen announced the first patient dosed in the Phase 1/2 clinical trial evaluating the safety and efficacy of OCU410—modifier gene therapy—for geographic atrophy secondary to dry age-related macular degeneration. For more details, see the full press release.

[Tiffany Hamilton @tiffjeanne]

Great to see innovative vaccine solutions covered in JAMA and honored to have Ocugen included. #nextgen #vaccines #COVID19 #ocugen

[Ocugen @Ocugen]

Ocugen's mucosal vaccine candidate and participation in NIAID Project NextGen clinical trials cited in @JAMA_current. To read more, visit: https://t.co/cbXfH7DFae

[Tiffany Hamilton @tiffjeanne]

@PhilMartelli @Phillies Love this, Phil. You are missed!

[Tiffany Hamilton @tiffjeanne]

Exciting news for our vaccines program! OCU500 has been selected by NIAID to participate in Project NextGen, a $5 billion U.S. government sponsored program to identify the next generation of vaccines and therapeutics to prevent the spread of COVID-19.

[Ocugen @Ocugen]

Today, Ocugen announced that our breakthrough inhalation vaccine platform received support from NIAID! Ocugen looks forward to this next step and further supporting the Company’s commitment to advancing public health. Read more at https://t.co/51WUEFQJaY

[Ocugen @Ocugen]

Ocugen's Dr. Shankar Musunuri recently sat down with Jared Taylor from Slice of Healthcare to share more on how the Company began, the depth of our scientific platforms, and recent accomplishments. Check out the first clip, and stay tuned! https://t.co/Jk2cxy9fKw

[Ocugen @Ocugen]

Dr. Shankar Musunuri will present at the 2023 Cell & Gene Meeting on The Mesa on 10/11 in Carlsbad, CA. He will provide an overview of Ocugen's clinical development programs and more about the recent positive Ph 1/2 OCU400 data results. To read more, visit:https://t.co/maagnEIE5J

[Ocugen @Ocugen]

Today is #WorldRetinaDay! We are focused on discovering, developing, and commercializing novel gene therapies that improve health & offer hope for patients across the globe, including those living with degenerative retinal conditions and inherited retinal diseases. #genetherapy

[CGTLive® @CGT_Live]

The data, reported by Ocugen on September 13, 2023, is an update on results previously reported in April of this year.

#LeberCongenitalAmaurosis #RetinitisPigmentosa #genetherapy

Read more:

https://t.co/7pgWX556oB

[Tiffany Hamilton @tiffjeanne]

Come join us in NYC next week and learn more about our first-in-class programs! #ocugen

[Ocugen @Ocugen]

Dr. Shankar Musunuri, Chairman, CEO and Co-founder of Ocugen, will participate in a panel at the annual Cantor Fitzgerald Global Healthcare Conference on September 26, 2023. To read more, visit: https://t.co/ryyZjMLVPE

[Tiffany Hamilton @tiffjeanne]

Today was an exciting day at Ocugen, as we shared the latest data set in the OCU400 Phase 1/2 clinical trial. We believe that OCU400—which utilizes a proprietary modifier gene therapy platform—has the potential to be a gene-agnostic therapeutic for RP and LCA patients #ocugen

[Ocugen @Ocugen]

We are pleased to announce a positive clinical study update from the Phase 1/2 trial of OCU400. To read more, visit: https://t.co/g67Q1oxjC1
#genetherapy #retinitispigmentosa #ocugen

[Tiffany Hamilton @tiffjeanne]

Join us tomorrow morning!

[Ocugen @Ocugen]

Tomorrow, Ocugen will host a webcast to review updated results from our Phase 1/2 trial of OCU400 for the treatment of retinitis pigmentosa (RP) and Leber congenital amaurosis (LCA). To read more, visit: https://t.co/DJVcaIeQ47

[Tiffany Hamilton @tiffjeanne]

@tomdurso Needs a better PR person, for sure!